| Refining genotype–phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan C Godfrey, E Clement, R Mein, M Brockington, J Smith, B Talim, V Straub, ... Brain 130 (10), 2725-2735, 2007 | 463 | 2007 |
| Delivery of therapeutic oligonucleotides with cell penetrating peptides P Boisguérin, S Deshayes, MJ Gait, L O'Donovan, C Godfrey, CA Betts, ... Advanced drug delivery reviews 87, 52-67, 2015 | 276 | 2015 |
| Dystroglycanopathies: coming into focus C Godfrey, AR Foley, E Clement, F Muntoni Current opinion in genetics & development 21 (3), 278-285, 2011 | 273 | 2011 |
| Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment C Betts, AF Saleh, AA Arzumanov, SM Hammond, C Godfrey, ... Molecular Therapy-Nucleic Acids 1, 2012 | 238 | 2012 |
| Brain involvement in muscular dystrophies with defective dystroglycan glycosylation E Clement, E Mercuri, C Godfrey, J Smith, S Robb, M Kinali, V Straub, ... Annals of Neurology: Official Journal of the American Neurological …, 2008 | 182 | 2008 |
| Fukutin gene mutations in steroid‐responsive limb girdle muscular dystrophy C Godfrey, D Escolar, M Brockington, EM Clement, R Mein, ... Annals of Neurology: Official Journal of the American Neurological …, 2006 | 181 | 2006 |
| Delivery is key: lessons learnt from developing splice‐switching antisense therapies C Godfrey, LR Desviat, B Smedsrød, F Piétri‐Rouxel, MA Denti, P Disterer, ... EMBO molecular medicine 9 (5), 545-557, 2017 | 161 | 2017 |
| Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy TC Roberts, KEM Blomberg, G McClorey, SEL Andaloussi, C Godfrey, ... Molecular Therapy-Nucleic Acids 1, 2012 | 152 | 2012 |
| How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse C Godfrey, S Muses, G McClorey, KE Wells, T Coursindel, RL Terry, ... Human molecular genetics 24 (15), 4225-4237, 2015 | 143 | 2015 |
| Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA P Järver, T Coursindel, SEL Andaloussi, C Godfrey, MJA Wood, MJ Gait Molecular Therapy-Nucleic Acids 1, 2012 | 133 | 2012 |
| A comparative study of α‐dystroglycan glycosylation in dystroglycanopathies suggests that the hypoglycosylation of α‐dystroglycan does not consistently correlate with clinical … C Jimenez‐Mallebrera, S Torelli, L Feng, J Kim, C Godfrey, E Clement, ... Brain Pathology 19 (4), 596-611, 2009 | 133 | 2009 |
| Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? MF Nordness, S Hamel, CM Godfrey, C Shi, DB Johnson, LW Goff, ... American Journal of Transplantation 20 (3), 879-883, 2020 | 124 | 2020 |
| Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover TC Roberts, C Godfrey, G McClorey, P Vader, D Briggs, C Gardiner, ... Nucleic acids research 41 (20), 9500-9513, 2013 | 101 | 2013 |
| Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant EM Clement, C Godfrey, J Tan, M Brockington, S Torelli, L Feng, ... Archives of Neurology 65 (1), 137-141, 2008 | 97 | 2008 |
| Relative frequency of congenital muscular dystrophy subtypes: analysis of the UK diagnostic service 2001–2008 EM Clement, L Feng, R Mein, CA Sewry, SA Robb, AY Manzur, E Mercuri, ... Neuromuscular Disorders 22 (6), 522-527, 2012 | 84 | 2012 |
| Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment MJ Gait, AA Arzumanov, G McClorey, C Godfrey, C Betts, S Hammond, ... nucleic acid therapeutics 29 (1), 1-12, 2019 | 76 | 2019 |
| Muscular dystrophies due to defective glycosylation of dystroglycan F Muntoni, M Brockington, C Godfrey, M Ackroyd, S Robb, A Manzur, ... Acta Myologica 26 (3), 129, 2007 | 64 | 2007 |
| Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice CA Betts, AF Saleh, CA Carr, SM Hammond, AML Coenen-Stass, ... Scientific reports 5 (1), 8986, 2015 | 62 | 2015 |
| Effectiveness of 1: 1 speech and language therapy for older children with (developmental) language disorder SH Ebbels, L Wright, S Brockbank, C Godfrey, C Harris, H Leniston, ... International journal of language & communication disorders 52 (4), 528-539, 2017 | 56 | 2017 |
| Correlating in vitro splice switching activity with systemic in vivo delivery using novel ZEN-modified oligonucleotides SM Hammond, G McClorey, JZ Nordin, C Godfrey, S Stenler, KA Lennox, ... Molecular Therapy-Nucleic Acids 3, 2014 | 48 | 2014 |
Cecilia Jimenez-MallebreraHospital Sant Joan de Deu Barcelona在 hsjdbcn.org 的电子邮件经过验证
